Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 16;1(1):1-10.
doi: 10.3109/21556660.2011.639418. eCollection 2012.

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

Oliver Bruder  1 , Christoph J Jensen  1 , Michael Bell  1 , Reinhard Rummel  2 , Guenter Boehm  3 , Sven Klebs  4 , Christian Sieder  4 , Jochen Senges  5
Affiliations

Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

Oliver Bruder et al. J Drug Assess. .

Abstract

Background: Left ventricular hypertrophy (LVH), a marker of cardiac end-organ damage, is frequently found in patients with arterial hypertension and is associated with cardiovascular and cerebrovascular morbidity and mortality. Therefore, LVH regression is an important treatment goal. For amlodipine plus valsartan (A/V) no specific study on LVH has been reported to date.

Methods: Prospective, open-label, randomized parallel-group study. Patients with essential hypertension and LVH were randomized to 52-week treatment with A/V 10/160 mg (n = 43) or the active comparator losartan/HCT 100/25 mg (L/H, n = 47). Add-on medication was allowed in case of inadequate blood pressure control. LV parameters were measured by cardiovascular magnetic resonance imaging (MRI), and adjudicated in a blinded manner. Study identifiers were NCT00446563 and EudraCT 2006-001977-17.

Results: In addition to the study treatment, 35% of patients in the A/V group and 49% in the L/H group received additional antihypertensive medication. Compared to baseline, both treatments reduced measures of LVH significantly after 52 weeks (e.g. LV mass index in the A/V group from 64.7 g/m(2) by -3.5 g/m(2), in the L/H group from 69.1 g/m(2) by -4.4 g/m(2), p < 0.01 for both). LV ejection fraction and LV volumes were not significantly changed by any regimen. A/V and L/H treatments were well tolerated.

Conclusions: Both regimen were effective in reducing LV mass compared to baseline and were well tolerated.

Keywords: A/V, amlodipine plus valsartan; Arterial hypertension; Asc. aorta, ascending aorta; BP, diastolic blood pressure; CCB, calcium channel blockers; IVS, interventricular septum thickness; L/H, losartan/hydrochlorothiazide; LA, left atrium; LVEDV, left ventricular enddiastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular endsystolic volume; LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVMI, left ventricular mass index; MRI, magnetic resonance imaging; RAAS; SBP, systolic blood pressure; combination therapy; end-organ damage; left ventricular hypertrophy; magnetic resonance imaging; norm BSA, adjusted for body surface area; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study design.
Figure 2.
Figure 2.
Patient flow.
See this image and copyright information in PMC

References

    1. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens 1998;16(6):715-23 - PubMed
    1. Sukhija R, Aronow WS, Kakar P, et al. Prevalence of echocardiographic left ventricular hypertrophy in persons with systemic hypertension, coronary artery disease, and peripheral arterial disease and in persons with systemic hypertension, coronary artery disease, and no peripheral arterial disease. Am J Cardiol 2005;96(6):825-6 - PubMed
    1. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322(22):1561-6 - PubMed
    1. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114(5):345-52 - PubMed
    1. Fleischmann EH, Schmieder RE. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep 2002;4(6):474-8 - PubMed

Associated data

LinkOut - more resources